Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes-Reference-Cited by-同舟云学术

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes

Published:2014-01 Issue:1 Volume:38 Page:29-33
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Prebet Thomas,Braun Thorsten,Beyne-Rauzy Odile,Dreyfus Francois,Stammatoullas Aspasia,Wattel Eric,Ame Shanti,Raffoux Emmanuel,Delaunay Jacques,Charbonnier Aude,Adès Lionel,Fenaux Pierre,Vey Norbert

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

2. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B;Silverman;J Clin Oncol,2002

3. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

4. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure;Prebet;J Clin Oncol,2011

5. Epigenetics in cancer;Esteller;N Engl J Med,2008

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Histone methyltransferases as a new target for the epigenetic action by vorinostat;Биохимия;2023-12-15

2. Histone Methyltransferases as a New Target for Epigenetic Action of Vorinostat;Biochemistry (Moscow);2023-07

3. Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism;Frontiers in Oncology;2021-09-28

4. Azacitidine in adult patients with acute myeloid leukemia;Critical Reviews in Oncology/Hematology;2017-08

5. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings;Expert Opinion on Pharmacotherapy;2017-08-01